Table 1.
Characteristics of the included studies
| References | Country | Patient number | Number of cases with AF recurrence | CA details | Mean follow-up months | Type of study | NOS | Risk factors involved |
|---|---|---|---|---|---|---|---|---|
| Koyama et al. [55] | Japan | 186 | 72 | RF-CPVI | 6 | cohort study |
9 (4/2/3) |
ER |
| Wokhlu et al. [15] | USA | 774 | 277 | RF-CPVI | 36 | cohort study |
9 (4/2/3) |
Diabetes, LAD, AF Types |
| Yang et al. [51] | China | 138 | 80 | RF-CPVI plus | 9.5 | cohort study |
9 (4/2/3) |
LAD |
| Yoshida et al. [30] | USA | 79 | 13 | RF-CPVI | 6 | cohort study |
9 (4/2/3) |
Age, Ablation time |
| Gu et al. [47] | China | 150 | 36 | RF-CPVI | 22.9 | cohort study |
9 (4/2/3) |
LAD |
| Cha et al. [16] | USA | 368 | 97 | RF-CPVI | 12 | cohort study |
9 (4/2/3) |
AF Types, CHF, Female |
| Richter et al. [52] | Austria | 30 | 16 | RF-CPVI | 6 | cohort study |
9 (4/2/3) |
hs-CRP |
|
Roland Richard (2012) |
Germany | 202 | 111 |
RF-CPVI plus |
56 | cohort study |
9 (4/2/3) |
AF duration |
| Sotomi et al. [53] | Japan | 392 | 40 | RF-CPVI | 32.4 | case control study |
7 (3/2/2) |
hs-CRP |
| Morris et al. [23] | Germany | 84 | 19 | RF-CPVI | 19.2 | cohort study |
9 (4/2/3) |
CHF |
| Kalil et al. [48] | Brazil | 102 | 33 |
RF-CPVI plus |
8 | cohort study |
9 (4/2/3) |
LAD |
| Park et al. [28] | Korea | 576 | 80 |
RF-CPVI plus |
13.1 | cohort study |
9 (4/2/3) |
Age, ER |
| Deftereos et al. [18] | Greece | 206 | 83 | RF-CPVI | 15 | cohort study |
9 (4/2/3) |
LAD, CHF |
| Kumar et al. [38] | USA | 124 | 49 | RF-CPVI | 11.8 | case control study |
8 (3/2/3) |
AF Types |
| Kim et al. [37] | Korea | 665 | 176 |
RF-CPVI plus |
19.3 | cohort study |
9 (4/2/3) |
AF Types |
| Bohó et al. [34] | Slovakia | 205 | 15 | CB-RFCA | 34 | case control study |
8 (3/2/3) |
AF Types |
| Teunissen et al. [40] | Netherlands | 509 | 299 | RF-CPVI | 66 | cohort study |
8 (4/2/2) |
AF Types, AF duration |
| Dallaglio et al. [17] | Spain | 666 | 19 | RF-CPVI | 45 | case control study |
7 (3/2/2) |
CHF, Female |
| Cabanelas et al. [49] | Spain | 94 | 42 | NA | NA | cohort study |
7 (4/2/1) |
LAD |
| Park et al. [43] | Korea | 141 | 103 | RF-CPVI | 25 | cohort study |
9 (4/2/3) |
AF duration, Age |
| Yingxian et al. [45] | China | 55 | 30 | NA | 40 | cohort study |
9 (4/2/3) |
AF duration |
| Deng et al. [19] | China | 1410 | 365 | RF-CPVI | 20.7 | case control study |
8 (3/2/3) |
AF Types, Age LAD, CHF |
| Carballo et al. [31] | Switzerland | 195 | 101 | RF-CPVI | 6 | cohort study |
9 (4/2/3) |
Ablation time, hs-CRP |
| Arora et al. [13] | USA | 37,360 | 1964 | NA | 3 | case control study |
8 (3/2/3) |
Diabetes female |
| Linhart et al. [39] | Spain | 94 | 40 | RF-CPVI | 15 | cohort study |
8 (4/2/2) |
AF Types |
| Kim et al. [26] | Korea | 874 | 195 |
RF-CPVI plus |
29.9 | cohort study |
8 (4/2/2) |
Age, LAVI |
| Knecht et al. [42] | Switzerland | 129 | 36 | RF-CPVI | 24 | cohort study |
9 (4/2/3) |
AF duration |
| Bisbal et al. [33] | Spain | 243 | 105 |
RF-CPVI CB-CPVI |
43 | cohort study |
9 (4/2/3) |
AF Types |
| Fredersdorf et al. [36] | Germany | 122 | 24 | RF-CPVI | 51.1 | cohort study |
8 (4/2/2) |
AF Types |
| Lambert et al. [24] | Czech Republic | 61 | 43 | RF-CPVI | 19.5 | cohort study |
9 (4/2/3) |
Female |
| Stabile et al. [32] | Italy | 2519 | 571 | RF-CPVI | 46.2 | cohort study |
9 (4/2/3) |
Ablation time, AF duration |
| Wang et al. [14] | USA | 351 | 134 | RF-CPVI | 29.5 | case control study |
8 (3/2/3) |
Diabetes, AF Types |
| Deng et al. [20] | China | 1407 | 365 |
RF-CPVI CB-CPVI |
20.7 | cohort study |
9 (4/2/3) |
AF Types, LAD, Age CHF, ER |
| Deng et al. [25] | China | 1410 | 365 | CB-CPVI | 20.7 | cohort study |
9 (4/2/3) |
AF Types, LAD, Age hs-CRP, ER |
|
Sabina Istratoaie (2019) |
Romania | 80 | 30 | RF-CPVI | 14 | case control study |
8 (3/2/3) |
LAVI |
| Shang et al. [50] | China | 100 | 31 | CB-CPVI | 13.4 | cohort study |
9 (4/2/3) |
LAD |
| Donnellan et al. [21] | USA | 591 | 271 |
RF-CPVI plus |
32 | cohort study |
9 (4/2/3) |
AF Types, LAVI |
| Donnellan et al. [35] | USA | 267 | 87 |
RF-CPVI plus |
29 | cohort study |
9 (4/2/3) |
CHF |
| Donnellan et al. [46] | USA | 478 | 220 | RF-CPVI | 29 | cohort study |
9 (4/2/3) |
LAD |
| Yu et al. [41] | Korea | 1005 | 313 |
RF-CPVI plus |
24 | cohort study |
9 (4/2/3) |
AF Types |
| Lili et al. [27] | China | 120 | 38 | CB-CPVI | 12 | case control study |
8 (3/2/3) |
LAD, Age,hs-CRP, AF duration |
| Shchetynska et al. [29] | Germany | 205 | 88 | NA | 21 | case control study |
8 (3/2/3) |
Age |
| Kaneko et al. [22] | Japan | 568 | 91 |
RF-CPVI CB-CPVI |
14 | case control study |
8 (3/2/3) |
CHF |
| Hodges et al. [88] | Denmark | 7339 | 2801 | NA | NA | cohort study |
9 (4/2/3) |
ER |
CB, cry balloon; LAD, left atrial dimension; LAVI, left atrial volume indexed; PV, Pulmonary Vein